Li Nianhu, Jiang Yunpeng, Wooley Paul H, Xu Zhanwang, Yang Shang-You
Department of Orthopedics, Affiliated Hospital to Shandong University of TCM, 16369 Jingshi Road, Jinan, 250014, Shandong, China.
J Orthop Sci. 2013 May;18(3):478-85. doi: 10.1007/s00776-013-0362-9. Epub 2013 Apr 4.
Osteoporosis is a common pathological condition that influences 20 % of women over 50 years of age. This condition decreases bone strength and increases the risk of bone fracture. Naringin is a major flavonoid found in grapefruit and an active compound extracted from a Chinese herbal medicine (Rhizoma Drynariae). Studies have shown that naringin possesses many pharmacological effects. The current study evaluated the influence of naringin on osteoblastic cell differentiation and proliferation, and assessed its therapeutic effects on a rat osteoporosis model.
The proliferation, differentiation, and function of rat bone marrow stromal cells (BMSCs) were determined following treatment with various concentrations of naringin. Ovariectomy (OVX)-induced osteoporotic rats were orally administered naringin daily at low, medium, and high dosages, while a control group received PBS for 2 months. Femoral X-ray images and microCT scans were used for bone mineral density (BMD) and BV/TV (bone volume/total volume) analyses, and histological assessments of left tibiae were employed to check for changes in trabecular thickness (Tb.Th) and trabecular space (Tb.Sp) in the groups.
Naringin was effective at enhancing the proliferation and osteogenic differentiation of BMSCs, and a concentration of 10 μg/ml prompted the highest levels of osteocalcin expression among the in vitro study groups. There appeared to be a delayed response pattern of BMSCs to the naringin treatment. Naringin also effectively reversed OVX-induced bone loss via increasing BMD, bone volume, and trabecular thickness. The medium dose (300 mg/kg) appeared to be the optimal dosage for delivering satisfactory therapeutic effects.
Naringin promotes the proliferation and differentiation of BMSCs, and increases osteocalcin expression. Naringin also effectively reverses ovariectomy-induced osteoporosis in rats. The study suggests that naringin administration may represent an effective treatment for osteoporosis.
骨质疏松症是一种常见的病理状况，影响着20%的50岁以上女性。这种状况会降低骨强度并增加骨折风险。柚皮苷是葡萄柚中发现的一种主要类黄酮，也是从中草药骨碎补中提取的一种活性化合物。研究表明，柚皮苷具有多种药理作用。本研究评估了柚皮苷对成骨细胞分化和增殖的影响，并评估了其对大鼠骨质疏松模型的治疗效果。
用不同浓度的柚皮苷处理大鼠骨髓间充质干细胞（BMSC）后，测定其增殖、分化和功能。对卵巢切除（OVX）诱导的骨质疏松大鼠，分别以低、中、高剂量每日口服给予柚皮苷，而对照组给予PBS，持续2个月。使用股骨X线图像和显微CT扫描进行骨密度（BMD）和骨体积/总体积（BV/TV）分析，并采用左胫骨组织学评估检查各组骨小梁厚度（Tb.Th）和骨小梁间隙（Tb.Sp）的变化。
柚皮苷能有效增强BMSC的增殖和成骨分化，在体外研究组中，10μg/ml的浓度促使骨钙素表达达到最高水平。BMSC对柚皮苷处理似乎存在延迟反应模式。柚皮苷还通过增加骨密度、骨体积和骨小梁厚度有效逆转了OVX诱导的骨质流失。中等剂量（300mg/kg）似乎是产生满意治疗效果的最佳剂量。
柚皮苷促进BMSC的增殖和分化，并增加骨钙素表达。柚皮苷还能有效逆转大鼠卵巢切除诱导的骨质疏松。该研究表明，给予柚皮苷可能是一种有效的骨质疏松治疗方法。
